• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Delayed-onset Clevudine-induced myopathy: A case report
Clevudine is one of oral anti-viral agents for chronic hepatitis B patients, which is introduced as a nucleoside analogue inhibiting viral reverse transcriptase. Previous case reports described that 4 –15% of patients with long-term treatment of clevudine developed drug-induced myopathy within 6–24 months from the administration. Pathologic evidence supporting mitochondrial cytotoxicity, clevudine-induced myopathy is recovered by discontinuation of causative agents within 4 months in most cas es. In contrast to the precedent cases, we reported a patient of exceptionally delayed myotoxicity after 6 years of clevudine therapy.
Source: Neuromuscular Disorders - September 10, 2016 Category: Neurology Authors: D. Yoo, J. Shin Source Type: research

Necrotizing myopathy in two patients after the use of Moringa (P2.137)
Conclusions:Analogous to statins, Moringa may be associated with necrotizing myopathy.Disclosure: Dr. Treidler has nothing to disclose. Dr. Arya has nothing to disclose. Dr. Seidman has nothing to disclose. Dr. Somasundaram has nothing to disclose. Dr. Anziska has received research support from Pfizer. Dr. Marchidann has nothing to disclose. Dr. Maccabee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Treidler, S., Arya, K., Seidman, R., Somasundaram, M., Anziska, Y., Marchidann, A., Maccabee, P. Tags: Myopathies & amp;amp; Myasthenia Gravis II Source Type: research

Necrotizing Myopathy Resulting In Myocarditis And Sudden Death
Necrotizing myopathy (NM), a type of idiopathic inflammatory myopathy (IIM), is an autoimmune disorder in which immune cells target skeletal muscle, resulting in muscle breakdown and weakness. Cardiac involvement in this disorder is rare. We highlight a case of autoantibody-negative NM complicated by myocarditis and sudden cardiac death.Case Report: A 45-year-old male with a history of hypertension, previous hepatitis B, and obesity presented with 6 months of progressive proximal lower extremity weakness.
Source: Journal of Cardiac Failure - September 30, 2020 Category: Cardiology Authors: Reynaldo Homero Sanchez, Jeremy Slivnick, Ashly Cordero Rivera, Ajay Vallakati Tags: 120 Source Type: research

Antiviral effect of entecavir switching therapy in chronic hepatitis B patients with clevudine-associated myopathy.
PMID: 23472271 [PubMed - in process]
Source: Korean J Gastroenter... - January 25, 2013 Category: Gastroenterology Authors: Tak WY Tags: Korean J Gastroenterol Source Type: research

EP.17Vaccination as possible trigger of anti-SRP mediated necrotizing myopathy - a case report
Immunomediated necrotizing myopathy (IMNM) belongs to a heterogeneous group of inflammatory myopathies caused by myositis-specific autoantibodies including anti –3-hydroxy-3- methylglutaryl-coenzyme A (anti-HMGCR) and anti–single recognition particle (anti-SRP). IMNM anti-SRP typically presents with proximal weakness, myalgia, elevated CK and necrosis with absence of inflammation on muscle biopsy. Objective: to describe a case of IMNM anti-SRP positive after vaccination. A 42-year-old female complained of myalgia and muscle weakness affecting the neck and shoulder girdle 2 weeks after vaccination for Yellow fever, Teta...
Source: Neuromuscular Disorders - September 30, 2019 Category: Neurology Authors: J. Cavalcanti, W. Lima, K. Turke, L. Silva, A. Carvalho Source Type: research

Respiratory failure as the prominent manifestation of entecavir-associated mitochondrial myopathy: a case report
Mitochondrial myopathy caused by the long-term use of nucleos(t)ide analogue in patients with chronic hepatitis B (CHB) is mostly characterized by myasthenia and myalgia. Cases with respiratory failure as the ...
Source: BMC Infectious Diseases - February 24, 2022 Category: Infectious Diseases Authors: Xiao Lin, Aixin Song, Sujun Zheng and Xinyue Chen Tags: Case report Source Type: research

Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion
Conclusions MtDNA depletion results in mitochondrial dysfunction in the lamivudine/telbivudine-associated neuromyopathy. Myopathy was characterised by mitochondrial dysfunction accompanied with neurogenic damage due to axonal neuropathy. Ultrastructure changes of mitochondria included vacuolisation, simplification of the cristae and homogenised matrix.
Source: Journal of Clinical Pathology - October 16, 2014 Category: Pathology Authors: Xu, H., Wang, Z., Zheng, L., Zhang, W., Lv, H., Jin, S., Yuan, Y. Tags: Liver disease, Open access, Hepatitis and other GI infections, Muscle disease, Musculoskeletal syndromes, Hepatitis (sexual health), Clinical diagnostic tests Original article Source Type: research

Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients
Conclusions: Long-term clevudine monotherapy is effective for suppression of serum HBV DNA level and normalization of serum alanine amino transaminase levels, but associated with occurrence of rtM204I mutation. Clevudine-induced muscular adverse events are not uncommon, although they are totally reversible after cessation of the treatment. Muscular adverse events and serum CK level should be carefully monitored during long-term treatment with clevudine.
Source: Hepatitis Monthly - March 31, 2013 Category: Infectious Diseases Source Type: research

Novel LAMP2 mutations in Chinese patients with Danon disease cause varying degrees of clinical severity.
This study described two Chinese cases of Danon disease in order to broaden the phenotypic and genetic spectrum. Methods: Clinical data were collected and LAMP2 mutations were analyzed. Results: Patient A had fluctuating limb weakness during 6 months follow-up and was diagnosed with drug-induced myopathy due to anti-hepatitis B therapy with lamivudine. However, the first muscle biopsy with large cytoplasmic vacuoles confused the diagnosis and led to the second biopsy that allowed for the final diagnosis. Patient B had severe cardiac disturbances leading to sudden death. Molecularly, patient A harbored a synonymous mutation...
Source: Clinical Neuropathology - April 2, 2014 Category: Pathology Authors: Luo SS, Xi JY, Cai S, Zhao CB, Lu JH, Zhu WH, Lin J, Qiao K, Wang Y, Ye ZR Tags: Clin Neuropathol Source Type: research

P039  Muscle wasting & amp; weakness: a rare presentation of sarcoidosis
Conclusion Symptomatic myopathy is present in only 0.5-2.5% of sarcoidosis patients. This unique case highlights the heterogeneity of this disease and the vital role different diagnostic modalities play in achieving the correct diagnosis. It is also pertinent that the lymphadenopathy, found incidentally via imaging, led to the diagnosis. Although notoriously a diagnosis of exclusion, this case emphasises the importance of considering sarcoidosis even in the absence of respiratory symptoms, a raised ACE or hypercalcaemia.Disclosure C. Tomlinson: None.A. Khan: None.D. Mukerjee: None.N. Bhadauria: None.
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research

Extra‐hepatic Effects of Nucleoside and Nucleotide Analogues in Chronic Hepatitis B Treatment
Abstract Oral nucleoside/nucleotide analogues (NAs) are the mainstay of therapy for patients with chronic hepatitis B, and are generally well tolerated. Despite this, the safety profile of NAs is of paramount importance since the majority of patients will require long‐term treatment. All NAs can potentially affect human DNA polymerase with decrease in mitochondrial DNA, leading to manifestations of mitochondrial toxicity. As a class effect therefore, NAs can potentially cause extra‐hepatic conditions such as myopathy, nephropathy, neuropathy, and lactic acidosis. Indeed, effects on muscles including myopathy and creati...
Source: Journal of Gastroenterology and Hepatology - December 27, 2013 Category: Gastroenterology Authors: James Fung, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen Tags: Solicited Review Source Type: research

Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment
Abstract Oral nucleoside/nucleotide analogues (NAs) are the mainstay of therapy for patients with chronic hepatitis B and are generally well tolerated. Despite this, the safety profile of NAs is of paramount importance since the majority of patients will require long‐term treatment. All NAs can potentially affect human DNA polymerase with decrease in mitochondrial DNA, leading to manifestations of mitochondrial toxicity. As a class effect, therefore, NAs can potentially cause extrahepatic conditions, such as myopathy, nephropathy, neuropathy, and lactic acidosis. Indeed, effects on muscles, including myopathy and creatin...
Source: Journal of Gastroenterology and Hepatology - February 19, 2014 Category: Gastroenterology Authors: James Fung, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen Tags: Review Source Type: research

ATI-2173, A Novel Liver-Targeted Non-Chain Terminating Nucleotide for HBV Cure Regimens.
Abstract ATI-2173 is a novel liver-targeted molecule designed to deliver the 5'-monophosphate of clevudine for the treatment of chronic hepatitis B. Unlike other nucleos(t)ides, the active clevudine-5'-triphosphate is a noncompetitive, non-chain terminating inhibitor of HBV polymerase that delivers prolonged reduction of viremia in both a woodchuck HBV model and in humans up to six months after cessation of treatment. However, long-term clevudine treatment was found to exhibit reversible skeletal myopathy in a small subset of patients and was subsequently discontinued from development. ATI-2173 was designed by mod...
Source: Antimicrobial Agents and Chemotherapy - June 14, 2020 Category: Microbiology Authors: Squires KE, Mayers DL, Bluemling GR, Kolykhalov AA, Guthrie DB, Reddy P, Mitchell DG, Saindane MT, Sticher ZM, Edpuganti V, De La Rosa A Tags: Antimicrob Agents Chemother Source Type: research

Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis
Conclusion: Statin use was safe and associated with a lower pooled risk of HCC development among adults with CLD. Given the bias with observation studies, prospective randomised trial is needed to confirm this finding.
Source: Journal of Clinical Gastroenterology - July 15, 2021 Category: Gastroenterology Tags: Liver, Pancreas & Biliary Tract: Original Articles Source Type: research

Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma.
Abstract Dermatomyositis is an idiopathic inflammatory myopathy with typical cutaneous manifestations. It has been proposed that dermatomyositis may be caused by autoimmune responses to viral infections. Previous studies have shown an association between dermatomyositis and malignant tumors such as ovarian cancer, lung cancer, and colorectal cancer. However, a chronic hepatitis B virus (HBV) infection associated with dermatomyositis and hepatocellular carcinoma (HCC) has been very rarely reported. Here, we report a rare case of dermatomyositis coinciding with HBV-associated HCC. A 55-year-old male was confirmed to...
Source: The Korean Journal of Internal Medicine - March 1, 2014 Category: Internal Medicine Authors: Yang SY, Cha BK, Kim G, Lee HW, Kim JG, Chang SK, Kim HJ Tags: Korean J Intern Med Source Type: research

Pages: 1  2  3